{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:29:03Z","timestamp":1762295343965,"version":"3.41.2"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>A coronavirus SARS-CoV-2, which has caused the pandemic viral pneumonia disease COVID-19, significantly threatens global public health, highlighting the need to develop effective and safe vaccines against its infection. In this study, we developed a novel DNA vaccine candidate against SARS-CoV-2 by expressing a chimeric protein of its receptor-binding domain (RBD) fused to a 33-bp sequence (11 aa) from the hepatitis B virus (HBV) preS1 region with a W4P mutation (W4P-RBD) at the N-terminal region and evaluated its immunogenicity. <jats:italic>In vitro<\/jats:italic> transfection experiments in multiple cell lines demonstrated that W4P-RBD vs. wild-type RBD protein (W-RBD) led to enhanced production of IL-6 and TNF\u03b1 at the transcription and translation levels, suggesting the adjuvant potential of N-terminal HBV preS1 sequences for DNA vaccines against SARS-CoV-2. W4P-RBD also led to enhanced production of IgG and IgA, which can neutralize and block SARS-CoV-2 infection in both blood sera and bronchoalveolar lavage (BAL) fluid from the lung in vaccinated mice. Additionally, W4P-RBD led to an enhanced T-cell-mediated cellular immune response under S1 protein stimulation. In summary, W4P-RBD led to robust humoral and cell-mediated immune responses against SARS-CoV-2 in vaccinated mice, highlighting its feasibility as a novel DNA vaccine to protect against SARS-CoV-2 infection.<\/jats:p>","DOI":"10.3389\/fimmu.2021.637654","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T04:54:58Z","timestamp":1614315298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation"],"prefix":"10.3389","volume":"12","author":[{"given":"Hyein","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Min","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyejun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bum-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg Microbes Infect."},{"key":"B2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(20)30920-X","article-title":"SARS-CoV-2 and viral sepsis: observations and hypotheses","volume":"395","author":"Li","year":"2020","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science."},{"key":"B5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature."},{"key":"B7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2951-z","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science."},{"key":"B9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMRPSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell."},{"key":"B10","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Wall","year":"2020","journal-title":"Cell."},{"key":"B12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralizing antibodies against SARS-CoV-2 and other human coronavirus","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/cr.2015.113","article-title":"A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein","volume":"25","author":"Li","year":"2015","journal-title":"Cell Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nm.4131","article-title":"A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation","volume":"22","author":"Modjarrad","year":"2016","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41422-020-0387-5","article-title":"A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2","volume":"30","author":"Tai","year":"2020","journal-title":"Cell Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41422-020-00392-7","article-title":"A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice","volume":"30","author":"Lu","year":"2020","journal-title":"Cell Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell."},{"key":"B18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature."},{"key":"B19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","article-title":"Subunit vaccines against emerging pathogenic human coronaviruses","volume":"11","author":"Wang","year":"2020","journal-title":"Front Microbiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1016\/j.vaccine.2006.10.031","article-title":"Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model","volume":"25","author":"Du","year":"2007","journal-title":"Vaccine."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e81587","DOI":"10.1371\/journal.pone.0081587","article-title":"A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines","volume":"8","author":"Du","year":"2013","journal-title":"PLoS ONE."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3389\/fimmu.2018.01093","article-title":"Chaperma-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles","volume":"9","author":"Kim","year":"2018","journal-title":"Front Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3390\/v11090799","article-title":"A novel bacterium-like particle vaccine displaying the MERS-CoV receptor-binding domain induces specific mucosal and systemic immune responses in mice","volume":"11","author":"Li","year":"2019","journal-title":"Viruses."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.vaccine.2018.02.065","article-title":"Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen","volume":"36","author":"Nyon","year":"2018","journal-title":"Vaccine."},{"key":"B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.antiviral.2016.12.019","article-title":"Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induces specific humoral and cellular immune response in mice","volume":"140","author":"Wang","year":"2017","journal-title":"Antivir Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3748\/wjg.v24.i10.1084","article-title":"Sex disparity in viral load, inflammation and liver damage in transgenic mice carrying full hepatitis B virus genome with the W4P mutation in the preS1 region","volume":"24","author":"Lee","year":"2018","journal-title":"World J Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12943-015-0303-7","article-title":"Male-specific hepatitis B virus large surface protein variant W4P potentiates tumorigenicity and induces gender disparity","volume":"14","author":"Lee","year":"2015","journal-title":"Mol Cancer."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1128\/JCM.01505-13","article-title":"Male-specific W4P\/R mutation in the preS1 region of hepatitis B virus, increasing the risk of progression of liver diseases in chronic patients","volume":"51","author":"Lee","year":"2013","journal-title":"J Clin Microbiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41421-020-00199-1","article-title":"Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement","volume":"6","author":"Zang","year":"2020","journal-title":"Cell Discov."},{"key":"B31","doi-asserted-by":"publisher","first-page":"15526","DOI":"10.1016\/j.cyto.2020.155256","article-title":"ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis","volume":"136","author":"Cloutier","year":"2020","journal-title":"Cytokine."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e35421","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS ONE"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3575134","article-title":"The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement","author":"Quinlan","year":"2020","journal-title":"SSRN."},{"key":"B34","doi-asserted-by":"publisher","first-page":"9318","DOI":"10.1128\/JVI.01049-10","article-title":"T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice","volume":"84","author":"Zhao","year":"2010","journal-title":"J Virol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1126\/science.abc8511","article-title":"Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications","volume":"369","author":"Mathew","year":"2020","journal-title":"Science."},{"key":"B36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3389\/fimmu.2020.01022","article-title":"Highlight of immune pathogenic response and hematopathologic effect in SARS-CoV, MERS-CoV, SARS-CoV-2 infection","volume":"11","author":"Liang","year":"2020","journal-title":"Front Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3389\/fimmu.2020.02033","article-title":"The comparative immunological characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 coronavirus infections","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1099\/vir.0.2008\/000349-0","article-title":"Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison","volume":"89","author":"Wright","year":"2008","journal-title":"J Gen Virol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.637654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T04:55:00Z","timestamp":1614315300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.637654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2021.637654"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.637654","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"article-number":"637654"}}